Breaking News Just Announced
This tiny telehealth stock is up over 50% in the past month.
Put it on your watchlist now

ACXP Insider Trading (Acurx Pharmaceuticals)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $74,605.84
Insider Selling (Last 12 Months): $0.00

Acurx Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Acurx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acurx Pharmaceuticals Share Price & Price History

Current Price: $5.23
Price Change: Price Increase of +0.34 (6.95%)
As of 11/29/2021 12:55 PM ET

This chart shows the closing price history over time for ACXP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
$1.4 Trillion Helium Crisis Creates Booming Opportunity For Investors
Did you know that helium is one of the most valuable resources on the planet? That's because almost every big tech company depends on it. And the world's helium supply is running dangerously low. That's bad news for big tech, but great news for helium investors.
And This One Company Just Made A Helium Discovery

Acurx Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/23/2021Carl SailerDirectorBuy5,161$4.84$24,979.24View SEC Filing Icon  
11/19/2021David P. LuciCEOBuy5,200$4.80$24,960.00View SEC Filing Icon  
11/19/2021Robert J. DeLucciaDirectorBuy5,034$4.90$24,666.60View SEC Filing Icon  
See Full Table
Insider Buying at Acurx Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Acurx Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Acurx Pharmaceuticals (NASDAQ:ACXP)

26.75% of Acurx Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Acurx Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2021Millennium Management LLC30,090$0.16M0.0%N/A0.297%Search for SEC Filing on Google Icon
11/15/2021Tocqueville Asset Management L.P.19,100$98K0.0%+91.0%0.189%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.6,515$33K0.0%N/A0.064%Search for SEC Filing on Google Icon
8/16/2021Tocqueville Asset Management L.P.10,000$64K0.0%N/A0.105%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Acurx Pharmaceuticals logo
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Read More on Acurx Pharmaceuticals

Today's Range

Now: $5.23
Low: $5.23
High: $5.31

50 Day Range

MA: $4.91
Low: $4.09
High: $5.64

52 Week Range

Now: $5.23
Low: $3.71
High: $8.74

Volume

431 shs

Average Volume

216,276 shs

Market Capitalization

$52.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Acurx Pharmaceuticals?

Acurx Pharmaceuticals' top insider investors include:
  1. Carl Sailer (Director)
  2. David P Luci (CEO)
  3. Robert J Deluccia (Director)

Who are the major institutional investors of Acurx Pharmaceuticals?

Acurx Pharmaceuticals' top institutional shareholders include:
  1. Millennium Management LLC — 0.30%
  2. Tocqueville Asset Management L.P. — 0.19%
  3. BlackRock Inc. — 0.06%

Which major investors are buying Acurx Pharmaceuticals stock?

During the last quarter, ACXP stock was purchased by institutional investors including:
  1. Millennium Management LLC
  2. Tocqueville Asset Management L.P.
  3. BlackRock Inc.
Within the previous year, these company insiders have bought Acurx Pharmaceuticals stock:
  1. Carl Sailer (Director)
  2. David P Luci (CEO)
  3. Robert J Deluccia (Director)
635% Growth For American Lithium Company After They Fight Back Against China
The USA is fighting an economic war with China over lithium. Until now, we've been losing (with China controlling 80% of lithium production). But this small lithium company could change that with their significant holdings in the hottest area of the US for lithium discoveries.
They've Already Seen 635% Growth In 2021